Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + PD-1 antibody + local intervention for advanced hepatocellular carcinoma
ChiCTR2400083799Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and PD-1 Monoclonal Antibody in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
fruquintinibPD-1 Monoclonal Antibody
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400083799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083799.